April 2016 Br J Cardiol 2016;23:68–72 doi:10.5837/bjc.2016.016 Online First
Fatemeh Homaei Shandiz, Afsoon Fazlinezhad, Ahmad Tashakori Beheshti, Hesam Mostafavi Toroghi, Golkoo Hosseini, Maliheh Bakaiyan
Introduction Breast cancer is one of the major public health problems; it is the second most common cancer among women and it has a high mortality rate.1 Doxorubicin, which is an antibiotic of the anthracycline group, has a cytotoxic antineoplastic activity and is commonly used in a broad spectrum of malignancies, either alone or in combination with other drugs. Despite its usefulness in chemotherapy of breast cancer, its cardiac side effects, such as cardiomyopathy and congestive heart failure, cause considerable limitations and obstacles for oncologists and cardiologists.2,3 Doxorubicin’s cardiotoxicity is mainly due to oxidative stress,
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits